
|Articles|November 1, 2004
Oral agent shows durable improvement in SUI patients
San Diego-Treatment with the dual neurotransmitter reuptake inhibitor duloxetine (Yentreve) results in durable improvement in symptoms of stress urinary incontinence, according to a study of open-label transition from placebo to active therapy.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: Diet and Prostate Cancer, with Stephen J. Freedland, MD
2
67Cu-SAR-bisPSMA continues to show promise in mCRPC
3
How menstrual cycles influence bladder and pelvic floor symptoms
4
RCMIGI trial supports feasibility of reduced margins in image-guided prostate radiotherapy
5




















